Overview

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Status:
Active, not recruiting

Trial end date:
2024-08-31

Target enrollment:

Participant gender:

Summary

This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: - Pembrolizumab - AMG386

Phase:

Phase 1

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Amgen
Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab
Trebananib